Mayumi Nakagawa

Federal Grant PI High Impact

Professor

Last publication 2025 Last refreshed 2026-05-22

faculty

Pathology, College of Medicine

mnakagawa@uams.edu

29 h-index 143 pubs 2,801 cited

Biography and Research Information

OverviewAI-generated summary

Mayumi Nakagawa's research focuses on understanding and enhancing T-cell responses to high-risk human papillomaviruses (HPVs). She is currently the Principal Investigator on a renewal grant from the NIH/National Cancer Institute, totaling $727,264, aimed at investigating and improving these immune responses.

Her recent publications reflect this focus, including work on the expansion of HPV-specific T cells in individuals receiving therapeutic vaccines, and the coinfections with oncoviruses in HPV+ individuals. Nakagawa also investigates the evaluation of DNA extraction protocols for studying cervical microbiota and strategies for promoting cancer prevention measures through online surveys and focus groups.

Nakagawa leads a research group at the University of Arkansas for Medical Sciences, where she holds the position of Professor in Pathology. Her scholarly contributions are recognized by an h-index of 29 and over 2,700 citations across more than 140 publications. She actively collaborates with colleagues at her institution, including Sumit K. Shah, Hannah Coleman, Takeo Shibata, and Yong‐Chen Lu, with whom she has co-authored multiple publications.

Metrics

  • h-index: 29
  • Publications: 143
  • Citations: 2,801

Selected Publications

  • A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
  • Impact of New Hematopoietic Progenitor Cell Collection Goals on Apheresis and Cell Therapy Laboratory Services (2025)
  • A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
    2 citations DOI OpenAlex
  • Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
    1 citation DOI OpenAlex
  • Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)
    5 citations DOI OpenAlex
  • A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
    2 citations DOI OpenAlex
  • Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures (2021)
    1 citation DOI OpenAlex
  • Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)
    13 citations DOI OpenAlex
  • Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
    11 citations DOI OpenAlex
  • An Online Survey and Focus Groups for Promoting Cancer Prevention Measures (2021)
    6 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $727,264 total

NIH/National Cancer Institute Contact PI Jul 2010 - Jun 2027

Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal

National Cancer Institute $727,264 R01

Grants & Funding

  • History of CIN-2 in Adolescents (Subcontract with UCSF 4023sc) NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco Principal Investigator
  • CD8 T-cell epitopes of high risk human papillomaviruses American Cancer Society, Inc. Principal Investigator
  • Natural History of HPV Infection to Neoplasia (Subcontract with UCSF 4166sc) NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco Principal Investigator
  • MRNA translational Control of Cell Cycle Progression American Cancer Society, Inc. Principal Investigator
  • Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH/Nat. Cancer Institute Principal Investigator
  • Nakagawa_CPPS Pilot Award UAMS Principal Investigator
  • Natural History of HPV-Infection to Neoplasia NIH/Nat. Cancer Institute - Pass Through: University of California, San Francisco Principal Investigator
  • Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH/Nat. Cancer Institute Principal Investigator

Collaboration Network

161 Collaborators 49 Institutions 15 Countries

Top Collaborators

Similar Researchers

Based on overlapping research topics